Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892055093> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2892055093 endingPage "TPS3118" @default.
- W2892055093 startingPage "TPS3118" @default.
- W2892055093 abstract "TPS3118 Background: EBV associated malignancies exhibits high amplification of PD-L1 as distinguished from EBV non-associated malignancies (Kim et al. Gastroenterology 2015; Chen et al. Clinical Cancer Research 2013). The up-regulation of PD-L1 restricts antitumor effect of EBV-CTLs by immune tolerance and results in poor prognosis of patients. Our previous work has generated PD-1-disrupted CTLs by CRISPR-Cas9 system which could up-regulate IFN-γ production and enhance cytotoxicity in tumor cell lines and mouse model (Su et al. Oncoimmunology 2016). Methods: This phase I/II prospective single center clinical study (clinicaltrials.gov NCT03044743) was designed to evaluate the safety of PD-1 knockout EBV-CTLs in treating EBV positive advanced stage malignancies. Patients included should be pathologically verified EBV positive stage IV gastric carcinoma, nasopharyngeal carcinoma or lymphoma progressed after standard treatment with measurable lesions. Patients will be divided into three groups and receive 2 to 4 cycles of cell therapy according to their tolerance. PD-1 knockout EBV-CTLs from autologous origin will be generated and 2 x 10^7/kg of specific T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20%, 30% and 50% respectively. To modify immune microenvironment, Fludarabine at 30mg/m2 and cyclophosphamide at 300mg/m2 will be administered 3 days (intravenous injection, i.v.) before cell infusion. Interleukin-2 will be given daily (i.v.) from the first day of the cell infusion for 5 consecutive days at the dose of 4000,000 international unit (IU)/day to sustain the survival of infused T cells. The adverse events will be evaluated after each cycle by Common Terminology Criteria for Adverse Events (CTCAE v4.0) as primary endpoint. Progression-free survival (PFS), the duration of the normalization of tumor marker and immunological markers will be evaluated as the secondary endpoints. Immunological markers will continuously be examined every two cycles. Clinical trial information: NCT03044743." @default.
- W2892055093 created "2018-09-27" @default.
- W2892055093 creator A5003040978 @default.
- W2892055093 creator A5004716187 @default.
- W2892055093 creator A5030659990 @default.
- W2892055093 creator A5044549205 @default.
- W2892055093 creator A5049692788 @default.
- W2892055093 creator A5057361452 @default.
- W2892055093 creator A5061468205 @default.
- W2892055093 creator A5064633706 @default.
- W2892055093 creator A5067410978 @default.
- W2892055093 creator A5075374055 @default.
- W2892055093 date "2018-05-20" @default.
- W2892055093 modified "2023-10-06" @default.
- W2892055093 title "A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies." @default.
- W2892055093 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.tps3118" @default.
- W2892055093 hasPublicationYear "2018" @default.
- W2892055093 type Work @default.
- W2892055093 sameAs 2892055093 @default.
- W2892055093 citedByCount "4" @default.
- W2892055093 countsByYear W28920550932018 @default.
- W2892055093 countsByYear W28920550932021 @default.
- W2892055093 crossrefType "journal-article" @default.
- W2892055093 hasAuthorship W2892055093A5003040978 @default.
- W2892055093 hasAuthorship W2892055093A5004716187 @default.
- W2892055093 hasAuthorship W2892055093A5030659990 @default.
- W2892055093 hasAuthorship W2892055093A5044549205 @default.
- W2892055093 hasAuthorship W2892055093A5049692788 @default.
- W2892055093 hasAuthorship W2892055093A5057361452 @default.
- W2892055093 hasAuthorship W2892055093A5061468205 @default.
- W2892055093 hasAuthorship W2892055093A5064633706 @default.
- W2892055093 hasAuthorship W2892055093A5067410978 @default.
- W2892055093 hasAuthorship W2892055093A5075374055 @default.
- W2892055093 hasConcept C121608353 @default.
- W2892055093 hasConcept C126322002 @default.
- W2892055093 hasConcept C154317977 @default.
- W2892055093 hasConcept C202751555 @default.
- W2892055093 hasConcept C203014093 @default.
- W2892055093 hasConcept C2776694085 @default.
- W2892055093 hasConcept C2776755627 @default.
- W2892055093 hasConcept C2779263901 @default.
- W2892055093 hasConcept C2779338263 @default.
- W2892055093 hasConcept C502942594 @default.
- W2892055093 hasConcept C55493867 @default.
- W2892055093 hasConcept C71924100 @default.
- W2892055093 hasConcept C86803240 @default.
- W2892055093 hasConcept C8891405 @default.
- W2892055093 hasConceptScore W2892055093C121608353 @default.
- W2892055093 hasConceptScore W2892055093C126322002 @default.
- W2892055093 hasConceptScore W2892055093C154317977 @default.
- W2892055093 hasConceptScore W2892055093C202751555 @default.
- W2892055093 hasConceptScore W2892055093C203014093 @default.
- W2892055093 hasConceptScore W2892055093C2776694085 @default.
- W2892055093 hasConceptScore W2892055093C2776755627 @default.
- W2892055093 hasConceptScore W2892055093C2779263901 @default.
- W2892055093 hasConceptScore W2892055093C2779338263 @default.
- W2892055093 hasConceptScore W2892055093C502942594 @default.
- W2892055093 hasConceptScore W2892055093C55493867 @default.
- W2892055093 hasConceptScore W2892055093C71924100 @default.
- W2892055093 hasConceptScore W2892055093C86803240 @default.
- W2892055093 hasConceptScore W2892055093C8891405 @default.
- W2892055093 hasIssue "15_suppl" @default.
- W2892055093 hasLocation W28920550931 @default.
- W2892055093 hasOpenAccess W2892055093 @default.
- W2892055093 hasPrimaryLocation W28920550931 @default.
- W2892055093 hasRelatedWork W1562262381 @default.
- W2892055093 hasRelatedWork W1874896398 @default.
- W2892055093 hasRelatedWork W2012316077 @default.
- W2892055093 hasRelatedWork W2126442701 @default.
- W2892055093 hasRelatedWork W2137804513 @default.
- W2892055093 hasRelatedWork W2349603434 @default.
- W2892055093 hasRelatedWork W2374391184 @default.
- W2892055093 hasRelatedWork W2420702794 @default.
- W2892055093 hasRelatedWork W4239886120 @default.
- W2892055093 hasRelatedWork W4385685231 @default.
- W2892055093 hasVolume "36" @default.
- W2892055093 isParatext "false" @default.
- W2892055093 isRetracted "false" @default.
- W2892055093 magId "2892055093" @default.
- W2892055093 workType "article" @default.